Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.
Also called NCT02086045
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 126 participants
- Sponsor
- Registry
-
NCT02086045
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Brazil, Denmark, Germany, New Zealand, Poland
- Registry status
- Completed
Technical summary
Registry record NCT02086045. Allocation not applicable; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
- Condition
- Coronary Artery Disease
- Intervention (Device)
- DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
- Lead sponsor
- Elixir Medical Corporation
Record details
- Record id
cardio:ct-nct02086045- Content hash
53c804c2f8157e34054a2f1817a5757f6694bc3abadb571472d81dafc2221b10